Fatty Acid Oxidation Disorder Market

Introduction

Fatty acid oxidation disorders are classified under rare and genetic disorders. In fatty acid oxidation disorder, the body is unable to produce or utilize particle enzyme which is required for oxidation of fatty acids. Absence of enzymes stops the breakdown of fatty acids and it’s eventually build up in the liver and other internal organs.

Fatty acid oxidation disorder leads to the body being unable to produce energy from fatty acids in the liver and muscles. People with fatty acid oxidation disorder can function normally with dietary adjustments and medications. According to the National Institutes of Health (NIH), the incidence of fatty acid oxidation disorder is 1 in 5,000-10,000 births globally.

Increased focus on determining coronavirus cure among leading biopharmaceutical companies lead to delay in research and development activities of fatty acid oxidation disorder market. There has been observed supply chain disruption due to restrictions laid on trading across borders by various countries.

The significant decline in hospital visits and treatment-seeking rates will have a temporary impact on fatty acid oxidation disorder market. Covid-19 has led to lockdown in several countries delaying manufacturing activities of fatty acid oxidation disorder market.

Fatty Acid Oxidation Disorder Market: Drivers and Restraints

The rise in the prevalence of rare and genetic disorders increases the demand for fatty acid oxidation disorder market. Increasing funding for research and development from leading biopharmaceutical companies is expected to fuel fatty acid oxidation disorder market growth.

For instance, in July 2020, Ultragenyx Pharmaceutical Inc., a market player in drug development for rare disorders announced U.S. Food and Drug Administration (FDA) approval of triheptanoin, a new drug used in the treatment of fatty acid oxidation disorder.

Advancement in technology and research and development activities is expected to fuel fatty acid oxidation disorder market growth. Lack of awareness about therapeutic options available for rare disorders is expected to hinder fatty acid oxidation disorder market growth. The stringent regulatory requirement for drug approval is a challenging factor for fatty acid oxidation disorder market growth.

Fatty Acid Oxidation Disorder Market: Segmentation

Based on the drug type	Levocarnitine Dextrose Riboflavin Others
Based on the route of administration	Oral  Intravenous
Based on the distribution channel	Hospital pharmacies Retail pharmacies Drug stores Online stores

Fatty Acid Oxidation Disorder Market: Overview 

Levocarnitine hold the majority of revenue share in fatty acid oxidation disorder market with the highest demand. Oral drugs are most common in fatty acid oxidation disorder market generating maximum revenue. Whereas, intravenous route of administration will observe a significant rise in demand with the development of injectable drugs in the fatty acid oxidation disorder market.

Hospital pharmacies contribute the largest share among the distribution channel in fatty acid oxidation disorder market. Online pharmacies will observe a significant rise in demand with increased market penetration in fatty acid oxidation disorder market.

Fatty Acid Oxidation Disorder Market: Region-wise Outlook

Major players in fatty acid oxidation disorder market include Biosynth AG, Daiichi Sankyo Ltd., Northeast Pharmaceutical Group Co., Ltd., Merck KGaA, Mylan Laboratories Limited, AminoScience LLC, Chengda Pharmaceuticals Co. Ltd., Sigma-Tau Pharmaceuticals, Bedford Laboratories, Spectrum Chemicals and Laboratory Products, Inc., and others.

The research report on fatty acid oxidation disorder market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.

It also contains projections using a suitable set of assumptions and methodologies. The research report on fatty acid oxidation disorder market provides analysis and information according to market segments such as drug type, route of administration, distribution channel, and region.

The report covers exhaust analysis on:

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico, Brazil)
• Europe (Germany, Italy, France, U.K, Spain, Russia)
• East Asia (China, Japan, South Korea)
• South Asia (India, ASEAN)
• Oceania (Australia, New Zealand)
• Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current, and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

To know more about delivery timeline for this report Contact Sales